Brit J Anaesth:80岁以上重症监护患者的短期死亡率

2022-05-02 MedSci原创 MedSci原创

欧洲ICU住院的老年患者短期死亡率的差异很大程度上可以归因于住院患者临床状况的差异。在该人群中确定的入院量-结局之间的关系需要进一步研究来明确。

年龄80岁以上的患者占所有入住ICU患者的五分之一。尽管危重症老年患者的数量不断增加,但直到最近,关于高龄重症监护患者(VIP)的流行病学数据很少。有限的证据表明,整个欧洲老年危重症成人的死亡率存在差异。

近日,麻醉学领域权威杂志British Journal of Anaesthesia上发表了一篇研究文章,研究人员的目的是调查ICU高龄患者死亡率的地区差异。

研究人员对两项国际前瞻性队列研究进行了多水平分析,纳入了16个欧洲国家的322名ICU患者中80岁以上的患者。该研究的主要结局是入院后30天内的死亡率。该研究的数据结果以95%置信区间和比值比(OR)来表示。

在8457例患者中,2944名患者(36.9%[35.9-38.0%])在30天内死亡。参与国家之间的原始死亡率差异很大(ICU的原始死亡率从10.1%[6.4-15.6%]到45.1%[41.1-49.2%]范围内波动,30天内的原始死亡率从21.3%[16.3-28.9%]到55.3%[51.1-59.5%])范围内波动。在对混杂变量进行调整后,各国间30天死亡率的差异显著小于ICU间的差异(中位OR为1.14 vs. 1.58)。人均医疗支出(OR=0.84 per $1000[0.75-0.94])和社会医疗保险(OR=1.43[1.01-2.01])与ICU死亡率相关,但在30天随访中,这些关联的方向和程度尚不确定。在ICU病房(OR=0.81/1000名每年ICU住院患者[0.71-0.94])和30天随访(OR=0.86[0.76-0.97]),入院量均与较低的死亡率相关。

由此可见,欧洲ICU住院的老年患者短期死亡率的差异很大程度上可以归因于住院患者临床状况的差异。在该人群中确定的入院量-结局之间的关系需要进一步研究来明确。

原始出处:

Jakub Fronczek. et al. Short-term mortality of patients ≥80 years old admitted to European intensive care units: an international observational study.British Journal of Anaesthesia.2022.https://www.bjanaesthesia.org/article/S0007-0912(22)00156-8/fulltext

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633634, encodeId=63f91633634f2, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Dec 04 04:52:11 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018162, encodeId=98eb20181628f, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sat Jan 28 15:52:11 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051770, encodeId=a32b2051e70b5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 31 23:52:11 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551224, encodeId=d31a15512247f, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Wed May 04 14:52:11 CST 2022, time=2022-05-04, status=1, ipAttribution=)]
    2022-12-04 AspirantSuo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633634, encodeId=63f91633634f2, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Dec 04 04:52:11 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018162, encodeId=98eb20181628f, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sat Jan 28 15:52:11 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051770, encodeId=a32b2051e70b5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 31 23:52:11 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551224, encodeId=d31a15512247f, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Wed May 04 14:52:11 CST 2022, time=2022-05-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1633634, encodeId=63f91633634f2, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Dec 04 04:52:11 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018162, encodeId=98eb20181628f, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sat Jan 28 15:52:11 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051770, encodeId=a32b2051e70b5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 31 23:52:11 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551224, encodeId=d31a15512247f, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Wed May 04 14:52:11 CST 2022, time=2022-05-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1633634, encodeId=63f91633634f2, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Dec 04 04:52:11 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018162, encodeId=98eb20181628f, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sat Jan 28 15:52:11 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051770, encodeId=a32b2051e70b5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 31 23:52:11 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551224, encodeId=d31a15512247f, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Wed May 04 14:52:11 CST 2022, time=2022-05-04, status=1, ipAttribution=)]
    2022-05-04 bioon6

相关资讯

Crit Care:重症监护患者代谢性酸中毒的发生率和处置

危重病患者早期代谢性酸中毒很常见。临床医生将早期碳酸氢钠用于病情较重的患者治疗,但不能校正酸中毒的严重程度。

Crit Care:重症监护患者呼气流量受限的患病率和危险因素

由此可见,EFL在ICU患者中很常见,并且与不良预后相关。在ICU住院的前三天内,患者发生EFL的主要决定因素是体液平衡是否良好。需要进一步的研究来评估限制性液体疗法是否可能与较低的EFL发生率相关。

Crit Care:重症监护患者多巴胺与患者结局的关系

在日本,多巴胺被广泛使用。这项研究的结果表明高剂量使用多巴胺会带来有害效应。